GD2-specific chimeric antigen receptor-modified T-cell therapy against advanced neuroblastoma
| Project/Area Number |
23591533
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | キメラ抗原受容体 / トランスポゾン / GD2 / 小児がん / がん免疫療法 / 遺伝子治療 / 神経芽腫 |
|---|
| Research Abstract |
We successfully generated chimeric antigen receptor (CAR)-modified T cells using piggyBac transposon and nucleofection systems, and efficiently expanded the CAR-T cells using a serum-free culture system.
GD2-specific CAR-T cells induced in vitro cell death to various extents against GD2-positive tumor cell lines (neuroblastoma, retinoblastoma, medulloblastoma, and glioblastom). Additionally, addition of the agent A markedly increased the anti-tumor ability.
Considering the simplicity, safety, and cost-benefit of non-viral gene modification, piggyBac transposon-based GD2-specific T-cell therapy may be a novel therapeutic option against pediatric neurogenic tumors.
|
Report
(4 results)
Research Products
(12 results)
-
[Journal Article] Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia2014
Author(s)
Saito S, Nakazawa Y, Sueki A, Matsuda K, Tanaka M, Yanagisawa R, Maeda Y, Sato Y, Okabe S, Inukai T, Sugita K, Wilson MH, Rooney CM, and Koike K.
-
Journal Title
Cytotherapy
Volume: (in press)
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
[Presentation] CD19-specific T-cell therapy for refractory Philadelphia-chromosome-positive acute lymphoblastic leukemia using PiggyBac transposon-based gene modification and low autoserum-containing, but xeno-free and tumor cell line-free culture system2012
Author(s)
Saito S, Nakazawa Y, Tanaka M, Yanagisawa R, Maeda Y, Inukai T, Sugita K, Wilson MH, Rooney CM, Koike K.
Organizer
15th American Society of Gene and Cell Therapy Annual Meeting
Place of Presentation
Philadelphia
Related Report
-
-
